Oncolytics Biotech Inc. (ONC.TO)
-Toronto 2.71 
0.09(3.21%) May 24, 3:59PM EDT
| Prev Close: | 2.80 |
|---|
| Open: | 2.79 |
|---|
| Bid: | 2.71 |
|---|
| Ask: | 2.78 |
|---|
| 1y Target Est: | 7.08 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.67 - 2.79 |
|---|
| 52wk Range: | 1.61 - 4.94 |
|---|
| Volume: | 59,965 |
|---|
| Avg Vol (3m): | 95,025 |
|---|
| Market Cap: | 229.69M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in CAD.
Headlines
- Oncolytics rises on melanoma study resultsAP(Wed, May 22)
- ONC Makes Bullish Cross Above Critical Moving Averageat Forbes(Wed, May 22)
- Oncolytics cancer drug meets mid-stage trial goal, shares riseat Reuters(Wed, May 22)
- Canada Stocks to Watch: Sears Canada, Oncolytics, Canaccord and moreat The Wall Street Journal(Wed, May 22)
- BRIEF-Oncolytics Biotech U.S.-listed shares jump 10.3 percent premarketat Reuters(Wed, May 22)
- Oncolytics Biotech® Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma TrialCNW Group(Wed, May 22)
- Oncolytics Biotech® Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma TrialPR Newswire(Wed, May 22)
- Media Advisory - Oncolytics Biotech® Inc. to Present at Bank of America Merrill Lynch Health Care ConferenceCNW Group(Tue, May 14)
- Media Advisory - Oncolytics Biotech® Inc. to Present at Bank of America Merrill Lynch Health Care ConferencePR Newswire(Tue, May 14)
- Oncolytics Biotech® Inc. Announces Director Election Results from its Annual and Special Meeting of ShareholdersCNW Group(Fri, May 10)
- Oncolytics Biotech® Inc. Announces Director Election Results from its Annual and Special Meeting of ShareholdersPR Newswire(Fri, May 10)
- Oncolytics Biotech® Inc. Announces First Quarter 2013 ResultsCNW Group(Thu, May 9)
- Oncolytics Biotech® Inc. Announces First Quarter 2013 ResultsPR Newswire(Thu, May 9)
- Oncolytics Biotech® Inc. Announces Details of 2013 Annual and Special Meeting of ShareholdersCNW Group(Mon, May 6)
- Oncolytics Biotech® Inc. Announces Details of 2013 Annual and Special Meeting of ShareholdersPR Newswire(Mon, May 6)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.32 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.09 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers.
View More